Cybin Inc. Common Stock HELP · Stock Open Cybin Inc. Common Stock in new tab
Cybin Inc. Common Stock Analysis (HELP)
Is Cybin Inc. Common Stock a good investment? Cybin Inc. Common Stock (HELP) is currently trading at 11.57 USD. Market analysts have a consensus price target of 35.49 USD. This suggests a potential upside from current levels.
Earnings Schedule: Cybin Inc. Common Stock is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -1.98.
Investor FAQ
Does Cybin Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cybin Inc. Common Stock?
Cybin Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -4.84.
Company Profile
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 10, 2020 | 0.149000 |
| Sept. 19, 2024 | 0.026316 |
Community Discussion